Niraparib (MK-4827)

Catalog No.S2741

Molecular Weight(MW): 320.39

Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Phase 3.

Cited by 2 Publications

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192

Cell Death Dis, 2017, 8(10):e3070

PubMed: 28981112

2 Customer Reviews

PARP1 silencing rescues PARP1/2 inhibitor sensitivity in the ERCC1-deficient population. Effect of PARP1 knockdown by siRNA on sensitivity of ERCC1-isogenic cell lines to niraparib. Cells were reverse-transfected with PARP1 siRNA and drug was added 48 h after transfection. Cells were exposed to the drug for 5 days. Error bars represent the s.d. from the mean of three independent experiments.

Oncogene 2013 32(47):5377-87. Niraparib (MK-4827) purchased from Selleck.

PAR synthesis is detected by immunofluorescence staining in A2780 and HO8910 treated with different concentration of berberine alone or in combination with niraparib (10 μM) for 48 h. Representative examples of immunofluorescence staining of PAR. Scale bar, 20 μm.

Cell Death Dis, 2017, 8(10):e3070. Niraparib (MK-4827) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
2.1 nM	3.8 nM

In vitro

In a whole cell assay, MK-4827 inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. It was demonstrated to be a potent and selective PARP-1 and PARP-2 inhibitor with IC50=3.8 and 2.1 nM, respectively. Furthermore, it displayed at least a 100-fold selectivity over PARP-3, V-PARP, and tankyrase-1, with IC50 = 1300, 330, and 570 nM, respectively. As well as inhibiting the growth of HeLa cell lacking BRCA-1 because of silencing by RNA interference, MK-4827 is able to inhibit the proliferation of cancer cell lines carrying natural BRCA-1 or BRCA-2 mutations. In MDA-MB-436 human mammary gland adenocarcinoma cells carrying BRCA-1 mutations, MK-4827 displayed CC50 = 18 nM, while in CAPAN-1 human pancreatic adenocarcinoma cells, which are BRCA-2 mutant, MK-4827 displayed CC50 = 90 nM. In contrast, normal human prostate and mammary epithelial cells are resistant to MK-4827, displaying antiproliferative effects in the micromolar range, thereby demonstrating the very high selective cytotoxicity from these PARP inhibitors in BRCA-1 and -2 mutant cancer cells compared to surrounding tissue^[2].

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
HeLa cells	MWrGeY5kfGmxbjDhd5NigQ>?		NH[3OGtKdmirYnn0bY9vKG:oIGDBVnAhcW5iaInkdo9o\W5icHXyc5hq\GVvaX7keYNm\CCqdX3hckBJ\UyjIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gSG5CNWSjbXHn[U1qdmS3Y3XkJHBCWnmuYYTpc44tKEWFNUC9NE4xODRizszN	M{jTUlE6QDd\|OUix
A549 cells	NEizbJZEgXSxdH;4bYNqfHliYYPzZZk>	NVTOVnFYPS15IHThfZM>	M4DHWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhfHKjboPm[YN1\WRid3n0bEBDWkODMjDzbHJPSSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA2KHSxIEeg[IF6eyCkeTDD[YxtXGm2ZYKtRox2\SCjc4PhfUwhS0N3ME2wMlAyOSEQvF2=	Mmm5NlU4PjFyOU[=
MDA-MB-436 cells	NIKzd5dRem:uaX\ldoF1cW:wIHHzd4F6	NFHUZ3k3KGSjeYO=	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01OzZiY3XscJMh\XiycnXzd4lv\yCEUlPBNUA2Ozl4IDugNWc,SSCvdYThcpQh[W[2ZYKgOkBl[Xm\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiQ1O1NF0yQCCwTR?=	M2\zPFE6QDd\|OUix
SUM1315MO2 cells	NWrNfHIzS3m2b4TvfIlkcXS7IHHzd4F6	NUTC[48{OTJiZHH5dy=>	MnnKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3VOOTNzNV3PNkBk\WyuczDjZZJzgWmwZzDCVmNCOSCvdYThcpQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgNVIh\GG7czDifUBE\WyuVHn0[ZIuSmy3ZTDhd5NigSxiQ1O1NF0xNjB{IN88US=>	MU[yOVc3OTB7Nh?=
DoTc2-4510 cells	Mly1R5l1d3SxeHnjbZR6KGG\|c3H5	NFPmdo02NTdiZHH5dy=>	MoXuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSI9V[zJvNEWxNEBk\WyuczDjZZJzgWmwZzDCVmNCOiCvdYThcpQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGNEPTB;MD6wNlMh\|ryP	M2DrXVI2PzZzMEm2
SUM149PT cells	MkTaR5l1d3SxeHnjbZR6KGG\|c3H5	MVK1MVch\GG7cx?=	NF3FSllEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXU1zNEnQWEBk\WyuczDjZZJzgWmwZzDCVmNCOSCvdYThcpQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGNEPTB;MD6wNlQh\|ryP	M4LNUFI2PzZzMEm2
UWB1.289 cells	NWjObmtRS3m2b4TvfIlkcXS7IHHzd4F6	MVS1MVch\GG7cx?=	MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVW2IyNjJ6OTDj[YxteyClYYLyfYlv\yCEUlPBNUBufXSjboSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNTD0c{A4KGSjeYOgZpkhS2WubGTpeIVzNUKudXWgZZN{[XluIFPDOVA:OC5yNU[g{txO	Mmf2NlU4PjFyOU[=
Capan1 cells	NFvI[JVEgXSxdH;4bYNqfHliYYPzZZk>		NIKzT\|JEgXSxdH;4bYNqfHliYXfhbY5{fCCEUlPBNk1l\W[rY3nlcpQhcHWvYX6gR4Fx[W5zIHPlcIx{NCCFQ{WwQVAvODlizszN	MkLrNlU4PjFyOU[=
Jurkat cells	MVzGeY5kfGmxbjDhd5NigQ>?		NWD4XoxzUW6qaXLpeIlwdiCxZjDQRXJROSCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwhfmmjYnnsbZR6KGGodHXyJFk3KGi{czDifUBOXFNiYYPzZZkhcW5icILld4Vv[2Vib3[gNVAxKHWPIH;mJJRmdW:8b3zvcYll\SxiRVO1NF0xNjJizszN	NHnQdZMzOzh3MEG5PS=>
BT20 cells	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=	MlvuOU04KGSjeYO=	M1\0e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJVOjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOUB1dyB5IHThfZMh[nliQ3XscHRqfGW{LVLseYUh[XO\|YYmsJGNEPTB;Mj6yJO69VQ>?	NF[1XmgzPTd4MUC5Oi=>
A2780 cells	MknqSpVv[3Srb36gZZN{[Xl?		NFnve4FKdmirYnn0bY9vKG:oIGDBVnAhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCqeXTyc4dmdiCyZYLvfIll\S2rbnT1Z4VlKFCDUonsZZRqd25iYomgZ4VtdC2kYYPl[EBie3OjeR?=	NFzzOYkzPTd4MUC5Oi=>

... Click to View More Cell Line Experimental Data

In vivo

MK-4827, a novel, orally bioavailable, PARP-1 and PARP-2 inhibitor, strongly enhanced the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant^[1]. It was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer^[2].

Protocol

Cell Research:^[2]	+ Expand Cell lines: HeLa BRCA1-silenced cells Concentrations: serial dilutions Incubation Time: 7 days Method: Proliferation assays were conducted in 96-well black viewplates, and 300 cells/well (250 cell/well for BRCA-1 wt) in culture medium, 190 μL/well (DMEM containing 10% FCS, 0.1 mg/mL penicillin-streptomycin, and 2 mM L-glutamine), were plated and incubated for 4 h at 37℃ under 5% CO2 atmosphere. Inhibitors were then added with serial dilutions, 10 μL/well to obtain the desired final compound concentration in 0.5% DMSO. The cells were then incubated for 7 days at 37℃ in 5% CO2 after which time viability was assessed. Briefly, with CellTiter-Blue solution prediluted 1:10 in medium, 100 μL/well was added and the cells left for 45 min at 37℃ under 5% CO2 and then a further 15 min at room temperature in the dark. The number of living cells was determined by reading the plate at fluorimeter, excitation at 550 nm and emission at 590 nm. Cell growth was expressed as the percentage growth with respect to vehicle treated cells. The concentration required to inhibit cell growth by 50% (CC50) was determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female nude mice Formulation: 0.5% Methocel in deionized water Dosages: 25 mg/kg twice daily or 50 mg/kg once daily Administration: oral administration (Only for Reference)

Cell Research:^[2]

+ Expand

Cell lines: HeLa BRCA1-silenced cells
Concentrations: serial dilutions
Incubation Time: 7 days
Method: Proliferation assays were conducted in 96-well black viewplates, and 300 cells/well (250 cell/well for BRCA-1 wt) in culture medium, 190 μL/well (DMEM containing 10% FCS, 0.1 mg/mL penicillin-streptomycin, and 2 mM L-glutamine), were plated and incubated for 4 h at 37℃ under 5% CO2 atmosphere. Inhibitors were then added with serial dilutions, 10 μL/well to obtain the desired final compound concentration in 0.5% DMSO. The cells were then incubated for 7 days at 37℃ in 5% CO2 after which time viability was assessed. Briefly, with CellTiter-Blue solution prediluted 1:10 in medium, 100 μL/well was added and the cells left for 45 min at 37℃ under 5% CO2 and then a further 15 min at room temperature in the dark. The number of living cells was determined by reading the plate at fluorimeter, excitation at 550 nm and emission at 590 nm. Cell growth was expressed as the percentage growth with respect to vehicle treated cells. The concentration required to inhibit cell growth by 50% (CC50) was determined.
(Only for Reference)

Animal Research:^[1]

+ Expand

Animal Models: Female nude mice
Formulation: 0.5% Methocel in deionized water
Dosages: 25 mg/kg twice daily or 50 mg/kg once daily
Administration: oral administration
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	64 mg/mL (199.75 mM)
	Ethanol	64 mg/mL (199.75 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 10% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Niraparib (MK-4827) SDF

Molecular Weight	320.39
Formula	C₁₉H₂₀N₄O
CAS No.	1038915-60-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03586661	Not yet recruiting	Deleterious BRCA1 Gene Mutation\|Deleterious BRCA2 Gene Mutation\|Endometrial Adenocarcinoma\|High Grade Ovarian Serous Adenocarcinoma\|Primary Peritoneal High Grade Serous Adenocarcinoma\|Recurrent Endometrial Carcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	February 2019	Phase 1
NCT03651206	Not yet recruiting	Ovarian Carcinosarcoma\|Endometrial Carcinosarcoma	ARCAGY/ GINECO GROUP\|Tesaro Inc.	January 2019	Phase 2\|Phase 3
NCT03553004	Not yet recruiting	Pancreatic Cancer	Anup Kasi\|Tesaro Inc.\|University of Kansas Medical Center	January 1 2019	Phase 2
NCT03695380	Not yet recruiting	OVARIAN CANCER	Hoffmann-La Roche	December 31 2018	Phase 1
NCT03598270	Not yet recruiting	Recurrent Ovarian Carcinoma	Grupo Español de Investigación en Cáncer de Ovario\|Hoffmann-La Roche\|Apices Soluciones S.L.\|Tesaro Inc.	November 2018	Phase 3
NCT03368729	Not yet recruiting	Metastatic Breast Cancer\|HER2 Positive Breast Carcinoma	University of Alabama at Birmingham\|Translational Breast Cancer Research Consortium\|Tesaro Inc.\|Susan G. Komen Breast Cancer Foundation\|Breast Cancer Research Foundation of Alabama	November 1 2018	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo studies?
Answer:
You can use the formulation 1% CMC-Na (suspension) for oral administration.

PARP Signaling Pathway Map

Related PARP Products0

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Olaparib (AZD2281, Ku-0059436)

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features:A potent PARP inhibitor (currently in late stage clinical trials).
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

Choose Your Country or Region

By Signaling Pathways

By product type

Niraparib (MK-4827)

Cited by 2 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Niraparib (MK-4827) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

Related PARP Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Niraparib (MK-4827)

Cited by 2 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Niraparib (MK-4827) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

Related PARP Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)